Abstract: Provided herein are methods and compositions for treating von Willebrand disease with platelets, platelet derivatives, and/or thrombosomes.

Abstract: Provided herein are compositions, and methods for administering a platelet derivative composition for reducing bleeding in a subject who is refractory to platelet transfusion. Methods herein can further include administering a platelet derivative composition to a subject having low platelet counts (e.g., having thrombocytopenia) and/or to maintain the number of platelets over a threshold amount, or to increase the number of platelets in the subject. Methods herein can include administering a therapeutic agent before and optionally after administering the platelet derivative composition to the subject. Methods herein can reduce or eliminate any dosing and/or scheduling adjustments of a therapeutic regimen due to a low platelet count.

Abstract: Provided herein are imaging agent-loaded cryopreserved platelets and platelet derivatives, such as MRI agent-loaded platelets and platelet derivatives, and methods of preparing and using the same. In some embodiments, methods of loading MRI agents into platelets include contacting platelets with an MRI agent and a cell penetrating peptide. In some embodiments, methods of preparing MRI agent-loaded cryopreserved platelets or platelet derivatives in a dried powder, wherein the MRI agent-loaded cryopreserved platelets or the MRI agent-loaded platelet derivatives comprise an MRI agent complex covalently bonded to the surface of the cryopreserved platelets or the platelet derivatives.

Abstract: Provided herein are methods for administering platelet derivatives, such as freeze-dried platelet derivatives (FDPDs) to a subject having Hermansky Pudlak Syndrome (HPS) or Bernard Soulier Syndrome (BSS), comprising administering an effective dose of the platelet derivatives in a platelet derivative composition to the subject. The platelet derivatives can have numerous characteristics provided herein, that make them well suited to restore hemostatic functions in the subject. In some embodiments, the platelet derivatives are from a pool of donors. Furthermore, provided herein are platelet derivatives, and methods using the same, that have numerous beneficial properties, as provided.

Abstract: In some embodiments provided herein is a method of treating a coagulopathy in a subject, the method including administering to the subject in need thereof an effective amount of a composition including platelets or platelet derivatives and an incubating agent including one or more salts, a buffer, optionally a cryoprotectant, and optionally an organic solvent, wherein the subject has been treated or is being treated with an antiplatelet agent.

Abstract: In some embodiments, provided herein is a composition comprising cryopreserved anti-cancer drug-loaded platelet composition, and a process for preparing the same, in illustrative embodiments, cryopreserved anti-cancer drug-loaded platelet composition can be stored at a temperature in a range of ?10° C. to ?30° C. for at least 1 month. The anti-cancer drug-loaded platelets in the composition can be platelet derivatives. In some embodiments provided herein are methods of preparing anti-cancer drug loaded platelet derivatives, or cryopreserved anti-cancer drug-loaded platelets, comprising: incubating platelets with an anti-cancer drug, and with a loading buffer comprising a monosaccharide and/or a disaccharide, to form anti-cancer drug-loaded platelets, and lyophilizing or freezing the anti-cancer drug-loaded platelets, to form anti-cancer drug loaded platelet derivatives, or cryopreserved anti-cancer drug-loaded platelets, respectively.

Abstract: Provided herein are methods and compositions for treating a coagulopathy in a subject. Such methods can include administering to the subject in need thereof, for example because they have been administered an anticoagulant agent, an effective amount of a composition including platelets, or in illustrative embodiments platelet derivatives, and in further illustrative embodiments freeze-dried platelet derivatives (FDPDs). Various properties of exemplary embodiments of such methods and platelet derivatives used therein, as well as numerous additional aspects and embodiments are provided herein.

Abstract: Provided herein are methods for administering platelet derivatives, such as freeze-dried platelet derivatives (FDPDs) to a subject, comprising administering an effective dose of the platelet derivatives in a platelet derivative composition to the subject. Such effective dose in illustrative embodiments, includes multiple individual doses, or a continuous dose administered within a time period, for example a time period of less than 4 hours. In certain aspects herein the subject is a subject having Hermansky Pudlak Syndrome (HPS). The platelet derivatives can have numerous characteristics provided herein that make them well suited to restore hemostatic functions in the subject. In some embodiments, the platelet derivatives are from a pool of donors, and are HLA Class 1-characterized platelet derivatives (e.g., FDPDs), which in certain illustrative embodiments are HLA Class 1-matched FDPDs.

Abstract: In some embodiments provided herein is a method of treating a coagulopathy in a subject, the method including administering to the subject in need thereof an effective amount of a composition including platelets or platelet derivatives and an incubating agent including one or more salts, a buffer, optionally a cryoprotectant, and optionally an organic solvent, wherein the subject has been treated or is being treated with an antiplatelet agent.

Abstract: Provided herein are MRI agent-loaded platelets, methods of preparing MRI agent-loaded platelets, and methods of using MRI agent-loaded platelets. In some embodiments, methods of loading MRI agents into platelets include contacting platelets with an MRI agent, a cell penetrating peptide, and a loading buffer that can include a salt, a base, a loading agent, and optionally at least one organic solvent.

Abstract: Provided herein are methods and compositions for treating von Willebrand disease with platelets, platelet derivatives, and/or thrombosomes.

Abstract: In some embodiments provided herein is a method of preparing cargo-loaded platelets, comprising: treating platelets with a cargo and with a loading buffer comprising a salt, a base, a loading agent, and optionally ethanol, to form the cargo-loaded platelets.

Abstract: In some embodiments provided herein is a method of treating a coagulopathy in a subject, the method including administering to the subject in need thereof an effective amount of a composition including platelets or platelet derivatives and an incubating agent including one or more salts, a buffer, optionally a cryoprotectant, and optionally an organic solvent.

Abstract: Provided herein are methods and compositions for treating von Willebrand disease with platelets, platelet derivatives, and/or thrombosomes.

Abstract: Provided herein are RNA agent-loaded platelets, methods of preparing RNA agent-loaded platelets, and methods of using RNA agent-loaded platelets. In some embodiments, methods of loading RNA agents into platelets include treating platelets with a RNA agent, a cationic transfection reagent, and a loading buffer that can include a salt, a base, a loading agent, and optionally at least one organic solvent.

Abstract: Provided herein are materials and methods for the preparation of blood products. In one aspect, provided herein is a composition including platelets or platelet derivatives and an aqueous medium, wherein the aqueous medium has a protein concentration less than 50% of the protein concentration of donor apheresis plasma.

Abstract: Provided herein are materials and methods for the preparation of blood products. In one aspect, provided herein is a composition including platelets or platelet derivatives and an aqueous medium, wherein the aqueous medium has a protein concentration less than 50% of the protein concentration of donor apheresis plasma.

Abstract: Provided herein is a composition of matter comprising dried blood plasma substantially free of blood cell components; and a) a resuscitative mixture comprising at least one saccharide, at least one salt, and at least one high molecular weight, non-ionic, hydrophilic polymer, b) platelets or platelet-derived material, or c) both a) and b).

Abstract: Provided herein are RNA agent-loaded platelets, methods of preparing RNA agent-loaded platelets, and methods of using RNA agent-loaded platelets. In some embodiments, methods of loading RNA agents into platelets include treating platelets with a RNA agent, a cationic transfection reagent, and a loading buffer that can include a salt, a base, a loading agent, and optionally at least one organic solvent.

Abstract: In some embodiments provided herein is a method of treating a coagulopathy in a subject, the method including administering to the subject in need thereof an effective amount of a composition including platelets or platelet derivatives and an incubating agent including one or more salts, a buffer, optionally a cryoprotectant, and optionally an organic solvent, wherein the subject has been treated or is being treated with an antiplatelet agent.